Nerventra (laquinimod)
- Region
- 🇪🇺 EU
- Active substance
- laquinimod
- Company
- Teva Pharma GmbH
- Status
- Refused
- Therapeutic area
- Multiple Sclerosis
- CHMP opinion
- Thu 22 May 2014
- Application
- EMEA/H/C/002546
- ATC
- N07
- Official record
- www.ema.europa.eu
Indication
Treatment of multiple sclerosis
Regulatory milestones
No milestones recorded in the last year.
Follow Nerventra
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.